1 / 13

Elissa Ladd, PhD, RN, FNP-BC ; Diane Mahoney, PhD, RN, GNP ; Sri Emani , PhD

“ UNDER THE RADAR”: NURSE PRESCRIBERS AND PHARMACEUTICAL INDUSTRY PROMOTIONS. Elissa Ladd, PhD, RN, FNP-BC ; Diane Mahoney, PhD, RN, GNP ; Sri Emani , PhD. Funding Source: US Attorneys General Consumer and Prescriber Grant Program*

edison
Download Presentation

Elissa Ladd, PhD, RN, FNP-BC ; Diane Mahoney, PhD, RN, GNP ; Sri Emani , PhD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. “UNDER THE RADAR”: NURSE PRESCRIBERS AND PHARMACEUTICAL INDUSTRY PROMOTIONS Elissa Ladd, PhD, RN, FNP-BC; Diane Mahoney, PhD, RN, GNP ;Sri Emani, PhD

  2. Funding Source: US Attorneys General Consumer and Prescriber Grant Program* * Resulted from a $430 million settlement that reconciled allegations of an unlawful marketing campaign for the drug Neurontin® that violated state consumer protection laws

  3. Background: APN Prescribing in the US • Advance Practice Nurse (APN) prescribers: nurse practitioners (NPs), certified nurse midwives (CNMs), mental health clinical nurse specialists, nurse anesthetists • > 150,000 NP APN prescribers (100,000 Family Physicians) – primary care • Statutory authority to prescribe in all 50 states (US) and the District of Columbia • 97% write prescriptions: 9 – 25/day; 6200Rx/NP/yr; 500 million prescriptions a year (Bacchetta & Green, 2007; Treise& Rausch, 2005)

  4. Pharmaceutical Industry Influence on Prescribing • Studies consistently show that promotion increases prescribing (Chren ,1994; Lurie,1990; Wazana,2000;Fischer,2009)) • Studies consistently show that both physicians and APN prescribers do not believe that promotion affects prescribing (Fisher et al., 2009; Crigger, et al., 2009) • NPs have an uncritically positive attitude toward pharmaceutical promotions (Fisher et al., 2009; Crigger, et al., 2009) • Paucity of empirical data on nurse prescribing behaviors in relation to pharmaceutical marketing

  5. METHODS:peRx: Prescribing Evidence Based Therapies • Web-based educational intervention on • pharmaceutical marketing, conflicts of • interest, and evidence-based prescribing • Produced in visually engaging entertaining format:

  6. Evaluation: Web-based surveys (2007-2008) • Baseline (n = 263) • Post 1 (n =208) - immediate • Post 2(n=189) – 8 weeks post intervention Three key domains: • Perceived reliability of information provided by industry • Acceptability of promotional items and meals • Self-reported prescribing practices.

  7. Selected Results: Baseline: • Nurse prescribers had broad interface with pharmaceutical industry promotions at baseline: • Representatives • Samples • Meal events • Continuing education

  8. Key Domains: PostIntervention

  9. Lessons Learned • Nurse prescribers (APNs) are clearly “flying under the radar” regarding research and programs that address: • Pharmaceutical industry interface with health care professionals • Programs re: Evidence base prescribing and use of generic medications • Broad interest from the academic community to integrate material into pre-professional and post-baccalaureate curricula (> 100 graduate programs)

  10. Policy Implications • Advance practice nurses (APNs) have the legal authority • to prescribe in seven western European and Anglo • Saxan countries; 4 other countries in the process of • introducing nurse prescribing*(HAI, 2011; Kroezen et • al.,2011) * Australia, Canada, Ireland, New Zealand, Sweden, the UK and the USA; The Netherlands and Spain pending regulatory approval; Finland: proposed Government approval; South Africa regulatory evaluation • Significant expansion of promotional activities that are • directed to nurse prescribers • Limited integration into programs that foster evidence • based prescribing, i.e. academic detailing, rational medicine use • education

  11. Nurses as Explicit and Implicit Prescribers • Explicit Prescribers: Formal or statutory authority to prescribe • Implicit Prescribers: Informal prescribers • Active participants in therapeutic choices of both prescribers and patients (medications and non-pharmacologic therapies) • 95% of nurses reported being asked by friends, family, or patients about prescription drugs (ANA, 2010) • Improve decision making for “as needed” medications in mental health care (Usher et al. 2009) • Instrumental in avoidance in errors and adverse events in prescribing (Plew-Ogan,et al., 2004)

  12. Nurses are the largest segment of the post-professional healthcare workforce worldwide (~ 17.6 million) (WHO,2010) • Task shifting • Compelling power to influence rational use of pharmacotherapeutics • Compelling potential to contribute to inter-professional strategies (research and programmatic models) for appropriate medicine use

  13. Thank you eladd@mghihp.edu

More Related